Monitor for clinical trial initiation announcements in Q2 2026 for DMD and regulatory engagement updates for ALS in H2 2026. The Takeda partnership provides significant non-dilutive funding for elritercept development.
Price Chart
Executive Summary
Keros Therapeutics updated its corporate presentation for investor meetings, disclosing clinical trial timelines and preclinical data for its drug candidates rinvatercept and elritercept. The company expects to initiate a Phase 2 trial for Duchenne Muscular Dystrophy in Q2 2026 and engage regulators on an ALS trial in H2 2026. The presentation also highlights the $1.3 billion global licensing deal with Takeda for elritercept.
Key Facts
- Updated corporate presentation includes clinical development timelines for rinvatercept (DMD and ALS) and elritercept (MDS)
- Phase 2 DMD trial expected to commence in Q2 2026
- Regulatory engagement for ALS trial planned in H2 2026
- Takeda licensing agreement for elritercept includes $200M upfront payment and over $1.1B in potential milestones
- Presentation contains forward-looking statements about clinical trial design and timing
Financial Impact
No new financial data disclosed, but the Takeda deal represents $1.3B in potential value
Risk Factors
- Clinical trial timelines are forward-looking and subject to delay
- No efficacy data presented - trial outcomes remain uncertain
- Company has limited operating history and historical losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000021 |
| Document: corporatepresentationmar.htm | 0001664710-26-000021 |
| Document: 0001664710-26-000021-index-headers.html | 0001664710-26-000021 |
| Document: 0001664710-26-000021-index.html | 0001664710-26-000021 |
| Document: 0001664710-26-000021.txt | 0001664710-26-000021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 23d ago | 8-K | $11.31 $11.04 | ▼ −2.39% | ▼ −2.05% | $11.17 (−1.24%) |
Aug 20, 2026 6w ago | Insider Cluster | $10.95 $11.23 | ▲ +2.56% | ▲ +1.44% | $11.17 (+2.01%) |
Aug 3, 2026 8w ago | 8-K | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Aug 3, 2026 8w ago | Press Release | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Jul 30, 2026 9w ago | 8-K | $10.07 $11.15 | ▲ +10.72% | ▲ +7.21% | $11.17 (+10.92%) |
Jul 22, 2026 10w ago | 8-K | $10.14 $10.22 | ▲ +0.79% | ▲ +0.31% | $11.17 (+10.16%) |
Jun 17, 2026 15w ago | Insider Cluster | $10.65 $10.41 | ▼ −2.25% | ▼ −0.59% | $11.17 (+4.88%) |
Jun 8, 2026 16w ago | Insider Cluster | $10.07 $10.24 | ▲ +1.69% | ▼ −0.72% | $11.17 (+10.92%) |
May 14, 2026 20w ago | 8-K | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
May 14, 2026 20w ago | Press Release | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access